Compare Abeona Therapeutics Inc (ABEO) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Shell PLC — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Shell PLC trades at $90.09 (market cap $250.44B). The key difference: Shell PLC is far larger — about 594.6× Abeona Therapeutics Inc's market cap, and Shell PLC pays a 3.45% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SHEL | |
|---|---|---|
Market Cap | $421.19M | $250.44B |
Sector | Health | Energy |
52-Week High | $7.45 | $94.15 |
52-Week Low | $4.17 | $70.31 |
Enterprise Value | $276.10M | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Shell (SHEL) trades at $89.95, up 1.64% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The stock shows attractive valuation with a P/E of 10.01 and P/S of 0.88, supported by robust cash flow and a 14.35% ROE. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments in renewables.
Outlook is positive with a $103.60 consensus price target and 69% buy ratings, though risks include commodity volatility and regulatory pressures. Earnings growth and debt reduction provide upside, while geopolitical tensions and energy transition uncertainties remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
